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Identification of di-substituted 
ureas that prevent growth of 
trypanosomes through inhibition of 
translation initiation
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Some 1,3-diarylureas and 1-((1,4-trans)−4-aryloxycyclohexyl)−3-arylureas (cHAUs) activate heme-
regulated kinase causing protein synthesis inhibition via phosphorylation of the eukaryotic translation 
initiation factor 2 (eIF2) in mammalian cancer cells. To evaluate if these agents have potential to inhibit 
trypanosome multiplication by also affecting the phosphorylation of eIF2 alpha subunit (eIF2α), 
we tested 25 analogs of 1,3-diarylureas and cHAUs against Trypanosoma cruzi, the agent of Chagas 
disease. One of them (I-17) presented selectivity close to 10-fold against the insect replicative forms 
and also inhibited the multiplication of T. cruzi inside mammalian cells with an EC50 of 1–3 µM and a 
selectivity of 17-fold. I-17 also prevented replication of African trypanosomes (Trypanosoma brucei 
bloodstream and procyclic forms) at similar doses. It caused changes in the T. cruzi morphology, 
arrested parasite cell cycle in G1 phase, and promoted phosphorylation of eIF2α with a robust 
decrease in ribosome association with mRNA. The activity against T. brucei also implicates eIF2α 
phosphorylation, as replacement of WT-eIF2α with a non-phosphorylatable eIF2α, or knocking down 
eIF2 protein kinase-3 by RNAi increased resistance to I-17. Therefore, we demonstrate that eIF2α 
phosphorylation can be engaged to develop trypanosome-static agents in general, and particularly by 
interfering with activity of eIF2 kinases.
Parasitic diseases caused by protozoa such as Chagas disease and African Trypanosomiasis still lack effective, 
safe, and highly accessible chemotherapy1–4. The available drugs are toxic, the treatments show a high degree of 
abandon due to aggressive side effects5 and resistance has been detected6. Currently, very few compounds are on 
clinical trials for Chagas disease and African Trypanosomiasis caused respectively by Trypanosoma cruzi and 
Trypanosoma brucei7,8.
Different approaches have been devised to identify new compounds to treat these diseases. Previous works 
have explored unique trypanosome biological processes to find new drug targets. Examples are studies tar-
geting cysteine proteases, farnesyl pyrophosphatase synthase, glyceraldehyde 3-phosphate-dehydrogenase, 
14α-demethylase and trans-sialidases9–11. The enzyme 14α-demethylase has gathered attention due to its essential 
role in biosynthesis of steroids. This enzyme is inhibited by azolic compounds originally developed as antifungal 
agents, which were subsequently repurposed for treatment of Chagas disease12,13. Although, the treatment with 
a 14α-demethylase inhibitor, called posaconazole, has shown promising results, this treatment did not elimi-
nate the parasite in most cases, probably due to differences in parasite strains14,15 and prompted combinatory 
therapies16.
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A second approach has been to perform high-throughput screenings to identify new active compounds. 
For example, natural product libraries were used to identify new lead molecules against T. cruzi, T. brucei and 
Leishmania17. It is also noteworthy that a set of 1.8 million compounds from GlaxoSmithKline tested against these 
parasites revealed possibly new therapeutic molecules, including kinase inhibitors18.
Since drug exposure is an environmental challenge for parasites and considering that, for most cases, differ-
ences in strains susceptibility are also a problem15, global molecular responses to different stresses, such as the 
drug treatment, could be explored as a tool to improve the chemotherapy of parasitic diseases. A similar approach 
has been proposed for pathogenic fungi, such as Candida albicans19, where a genome-wide transcriptional factor 
has a dual role during stress fine-tuning responses to drug exposure and resistance. The phosphorylation of eIF2α 
has been recognized as the “integrated stress response hub” for various organisms, arresting general translation 
and promoting the accumulation of proteins and enzymes that cope with different types of damaging situations20. 
However, when the phosphorylation is sustained for long periods, apoptosis and cell death are induced21.
Urea derivatives, particularly those substituted by cyclic rings, provide significant opportunities for drug 
development and some of them have been previously shown to trigger eIF2α phosphorylation in mammalian 
cells22–24, a key event in the stress response and cell survival, especially for cancer cells chemotherapy25. Some 
urea derivatives were found to activate the heme-regulated kinase, one of the four mammalian kinases that phos-
phorylate eIF2α, arresting cancer cell proliferation26. In addition, other substituted ureas could inhibit several 
enzymes27, prevent cellular growth28 and interfere with activation of intracellular complexes29.
Here, to exam the possible use of 1,3-di-substituted ureas in Trypanosomatids and to check whether they 
would also interfere with stress response and phosphorylation of eIF2α, we initially evaluated the activity of 25 
urea derivatives against T. cruzi epimastigotes, which are the free proliferating form found in the midgut of the 
insect vector. Three compounds were found effective in preventing parasite growth and one of them, named I-17, 
showed a better selectivity index, controlling the intracellular replicative form at 17-fold lower concentrations 
than the detected toxicity to human host cells. Therefore, we further evaluate the biological effects of I-17 treat-
ment and used T. brucei, which has more available genetic tools, to investigate how eIF2α phosphorylation and 
which eIF2α kinases were involved in growth inhibition by I-17.
Results
T. cruzi epimastigotes replication was inhibited by 1,3-diarylureas and cHAUs. T. cruzi epimas-
tigotes were incubated in culture medium for three days with 25 different compounds at 10 µM. Seventeen inhib-
ited parasite multiplication, while other 8 (3b, 3n, 3d, 3j, 3k, 3 l, 3t and NCPdCPU) were unable to produce any 
visible effect at 10 µM (data not shown). Therefore, we titrated the concentrations that caused 50% (EC50) and 
90% (EC90) viability inhibition for the 17 more active compounds using an Alamar Blue assay, which is based on 
the capacity of viable cells to reduce resazurin to resofurin. Nine compounds (3p, 6a, I-17, 3e, 6b, I-18, 3 g, 3r and 
3q) were most active against epimastigotes with EC50 concentrations ranging from 1.3 to 3.7 ± 2.5 µM (Table 1). 
The other eight presented EC50 values higher than 5 µM. We also tested benznidazole (BZN), a reference com-
pound for Chagas disease treatment, using the same Y strain and protocol to obtain an EC50 of 211 ± 3 µM. This 
is remarkable since even the less active of the 17 1,3-di-substituted ureas presented at least 25-fold higher activity 
compared to BZN using a resistant strain, demonstrating the susceptibility of T. cruzi to these compounds. To 
further select useful compounds, we determined the selectivity index by measuring viability of monkey kidney 
cells (LLC-MK2) for the most active compounds, also using Alamar Blue. As shown in Table I, the compounds 
were usually toxic for mammalian cells, except 3p, 6a and I-17, which were at least 5-fold more effective in dam-
aging parasites than host cells.
I-17 inhibited multiplication of different stages of T. brucei and T. cruzi parasites. As I-17 was 
the best among the 25 tested compounds, with a selectivity index of 9.5-fold over LLC-MK2 cells, we decided 
to further characterize its effects on different proliferative stages of T. cruzi and T. brucei. T. cruzi epimastigotes 
multiplication was diminished by 50% at ~3 µM I-17 (Fig. 1A), a value close to 3.4 µM, the EC50 concentration 
obtained by the Alamar Blue assay (Table I). In contrast, minimal inhibition was observed for all tested concen-
trations of NCPdCPU, one inactive 1,3-diarylureas (EC50>10 µM). We also observed that up to 10 µM, I-17 could 
be washed out and the parasites would re-start to multiply (data not shown), indicating that it has a trypanostatic 
effect on epimastigotes. We also tested the effect of I-17 in cultures of T. brucei bloodstream form (BSF) that corre-
sponds to the proliferative stage in mammalian host blood, and cultures that contained the procyclic form (PCF), 
the stage found in the gut of the insect vector. The multiplication of both forms was inhibited by I-17 but not by 
NCPdCPU (Fig. 1B). The inhibitory effect was more pronounced in PCF, starting to be detected at concentrations 
as low as 3 µM.
We observed that L6 rat myoblasts were also marginally affected after 72 hours incubation with up to 
5 µM I-17, using a lactate dehydrogenase activity assay as a biomarker for cytotoxicity and cytolysis (Fig. 1C). 
Furthermore, we tested whether I-17 could also inhibit the proliferation of T. cruzi amastigotes in infected L6 
cells. As shown in Fig. 1D, amastigote replication was strongly impaired when cells were treated with 3 µM I-17 
for 72 h. These results indicated that I-17 prevented replication of different stages of the two Trypanosoma species.
To further validate the selectivity in T. cruzi intracellular forms, we infected U-2 OS cells plated on 384 
well-microplates. The cells were treated with different concentrations of I-17 for 96 hours and the number of 
infected, non-infected cells and amastigotes was determined through high content analysis, which enables auto-
mated quantification of cells and parasites based on DNA staining (Fig. 1E). We found that I-17 caused a decrease 
in the numbers of T. cruzi amastigotes inside infected cells, with an EC50 of 1.2 ± 0.5 µM (Fig. 1F). In the same 
cultures, the host cell cytotoxicity was evaluated by counting the total number of cells in treated wells relative to 
the number of cells in non-treated wells, showing that I-17 was mildly toxic to host cells (EC50 = 21 ± 7.5 µM).
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I-17 changes trypanosomatids morphology and cell cycle. We observed aberrant cellular morphol-
ogy of epimastigotes incubated with I-17. After 4 hours incubation with 3 µM of I-17, the parasites rounded up, 
as visualized by immunofluorescence for tubulin, which is mainly found in the parasite subpellicular array of 
microtubules (Fig. 2A). This morphology was observed in 40% of the population treated with 3 µM I-17 and 
close to 90% in parasites incubated with 10 µM I-17 (Fig. 2B). Morphology changes also occurred in T. brucei 
PCF incubated with I-17 (data not show). Flow cytometry analysis indicated that I-17 treatment increased the 
percentage of T. cruzi epimastigote (Fig. 2C and D) and T. brucei PCF (Fig. 2E and F) population in the G1 cell 
cycle phase, suggesting an arrest of replication in both species.
I-17 induced eIF2α phosphorylation and protein synthesis arrest. Phosphorylation of eIF2α at ser-
ine 51 decreases protein synthesis in eukaryotic cells submitted to different types of stress20. This phosphorylation 
allows cells to translate preferentially proteins that act in stress remedial response30. We have previously found 
that T. cruzi epimastigotes phosphorylate eIF2α when submitted to nutritional stress31. The parasite eIF2α is 
phosphorylated in the threonine 169 (T169[P]), which corresponds to the serine 51 of most eukaryotes. Therefore, 
we tested whether eIF2α was phosphorylated when parasites were exposed to I-17. As shown in Fig. 3A, I-17 
treatment at 10 µM for 4 hours caused an increased phosphorylation of eIF2α detected by an specific antibody to 
T169[P], in comparison to non-treated cells (NT), in a similar manner to nutritional stress caused by incubating 
parasites in a saline medium (TAU), mimicking the urine of the insect vector32. The increase of eIF2α phospho-
rylation was observed and quantified in three independent experiments, showing similar results (Fig. 3B). An 
increase in T169[p] signal was also detected in PCF treated with I-17 for 24 hours (Fig. 3C).
These results suggest that I-17 could reduce general translation triggered by eIF2α phosphorylation. In fact, 
polysome profiling confirmed that less polysomes were present in cells treated with 10 µM I-17 in comparison 
with non-treated parasites (Fig. 3D). There was a large increase in RNA associated with the monosome (80 S) 
fractions compared to polysome fractions. The polysome to monosome ration (P/M) changed from 5.3 to 0.6 in 
Compound
T. cruzi epimastigotesa
LLC-MK2b EC50 (μM) Selectivity Indexc (SI)EC50 (μM) EC90 (μM)
3p 1.3d 4.4d 7.7 ± 3.7 5.9
6a 1.7 ± 0.1 7.5 ± 0.5 13.7 ± 8.7 8.0
I-17 3.4 ± 1.3 5.7 ± 1.5 32.4 ± 14.7 9.5
3e 2.3d 2.8d 6.6 ± 3.6 1.4
6b 2.5 ± 0.4 4.6 ± 0.1 2.5 ± 0.4 1.0
I-18 3 ± 0.7 6.6 ± 1.8 12.3 ± 8.8 4.1
3 g 3.3 ± 0.1 8.4 ± 2.4 7 ± 4.7 2.1
3r 3.5 ± 0.1 6 ± 0.9 8.6 ± 1.2 2.4
3q 3.7 ± 2.5 8.7 ± 1.0 1.2 ± 1.3 0.7
3 f 5.4 ± 0.2 16.8 ± 5.5 N.T.f N.T.
3o 5.5 ± 0.4 7.3 ± 0.8 N.T. N.T.
3 m 5.9 ± 0.3 7.7 ± 0.1 N.T. N.T.
3i 6.3 ± 0.5 12.1 ± 1.7 N.T. N.T.
I-m6 6.5 ± 0.2 10.4 ± 0.8 N.T. N.T.
3a 7.7 ± 0.5 9.9 ± 0.3 N.T. N.T.
3c 7.7 ± 0.4 9.7 ± 0.4 N.T. N.T.
3 h 8.2 ± 0.1 13.5 ± 4.5 N.T. N.T.
3b >10g >10 N.T. N.T.
3n >10 >10 N.T. N.T.
3d >10 >10 N.T. N.T.
3j >10 >10 N.T. N.T.
3k >10 >10 N.T. N.T.
3 l >10 >10 N.T. N.T.
3t >10 >10 N.T. N.T.
NCPdCPU >10 >10 N.T. N.T.
BZNe 211 ± 3.0 960 ± 25.0 N.T. N.T.
Table 1. Effective concentration (EC) in µM of 25 di-substituted urea compounds against T. cruzi epimastigotes 
and LLC-MK2 cells. aEpimastigotes of T. cruzi were incubated for 3 days in the presence of different 
concentrations of each compound in triplicate experiments, each value  determined in duplicate measurements. 
The concentration that inhibited 50% (EC50) or 90% (EC90) of multiplication was determined by using the 
Alamar Blue assay as described in Methods. bLLC-MK2 were plated and after 24 h, incubated with the different 
concentrations of the indicated compounds. After two more days, cell viability was measured with Alamar Blue 
assay as described in Methods and the results used to determine the (EC50). cTI = Ratio between T. cruzi EC50 
and LLC-MK2 EC50. dThese values correspond to a single experiment. eBZN = Benznidazole. fN.T. = not tested. 
g>10 = without apparent effect at 10 µM.
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control vs. I-17 treated samples respectively, indicating translation arrest at the initiation level. These data impli-
cate that I-17 may be causing translation initiation arrest as a consequence of eIF2α phosphorylation.
The effect of I-17 on T. brucei multiplication is dependent on eIF2α phosphorylation and on 
a specific kinase. To define a cause and effect relationship between eIF2α phosphorylation induction and 
I-17 inhibition of parasite multiplication, we examined the susceptibility of T. brucei BSF, in which one eIF2α 
allele was deleted and the other had threonine 169 replaced by alanine (T169A/−) to prevent phosphorylation. 
When comparing I-17 treated with non-treated cells (NT), expressed as relative cell numbers, the parasite strain 
expressing a non-phosphorylatable eIF2α (T169A/−) was consistently less susceptible to I-17 at 5 µM compared 
to the parasite line in which the endogenous eIF2α gene was replaced with wild type eIF2α (T169T/−), or with 
Figure 1. Replication of T. cruzi and T. brucei forms are inhibited by I-17. (A) T. cruzi epimastigotes were 
inoculated at 2 × 106 parasites per mL and incubated at 28 °C in LIT medium containing the indicated 
concentrations of NCPdCPU (an inactive 1,3-diarylurea, circles) or I-17 (squares). The numbers are 
means ± standard deviation (n = 3) of parasite counted after 48 hours of incubation. (B) T. brucei BSF (circles) 
and PCF (triangles) were inoculated at 2 × 105 parasites per mL in their respective culture media in the presence 
of the indicated concentrations of I-17, or NCPdCPU (closed symbols). The numbers are means ± standard 
deviation (n = 3) of parasites counted after 24 hours at 37 °C and 48 hours at 28 °C, respectively for BSF and PCF. 
(C) Relative viability of L6 myoblasts measured by activity of lactate dehydrogenase released after 72 hours in 
the presence of the indicated concentrations of I-17. (D) TCT was used to infect L6 cells. After infection the cells 
were treated for 72 hours with the indicated concentrations of I-17 and the number of intracellular amastigotes 
was determined by optical microscopy as described in Methods. The bars represent means ± standard deviation 
of three independent experiments. In all panels, *indicate p < 0.05, **p < 0.01 and ***p < 0.001 calculated 
using the Student’s T-test comparing to non-treated cells. (E) Serial dilutions of I-17 was used to treat U-2 
OS cells infected with T. cruzi TCT. Compound activity is indicated as percentage of parasite free cells (black 
circles) and the host cell survival (empty squares), both calculated as described in Methods. (F) Calculation of 
EC50 values for T. cruzi and host cells expressed in µM are also explained in Methods. The values in (E) and (F) 
represent means ± standard deviation of three independent experiments.
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the parental strain (+/+) containing original alleles (Fig. 4A). This indicates that eIF2α phosphorylation is one, 
albeit possible not an exclusive, mediator of the anti-trypanosome inhibition induced by I-17.
The phosphorylation of eIF2α is regulated by four kinases in mammals33. Trypanosomatids genome contains 
three eIF2α kinases; K1, K2 and K334. To identify which of these kinases could be involved in eIF2α phospho-
rylation by I-17, we generated knockdown lineages of PCF by RNAi for these three T. brucei kinases. We were 
able to obtain PCF lineages showing reduction of TbK1 and TbK3 RNA levels as seen by RT-PCR after induction 
of RNAi with tetracycline for 4 days (Fig. 4B). We could not obtain a conclusive knockdown of TbK2 (data not 
shown). As control, we found no changes in mRNA levels of enoyl CoA, a non-related enzyme. TbK1 and TbK3 
Figure 2. I-17 treatment causes aberrant morphology and G1 cell cycle arrest. (A) Epimastigotes non-treated 
(NT) or treated with 3 µM of I-17 for 4 hours were immunostained for β-tubulin (green) and labeled with 
DAPI to show the nucleus (N) and kinetoplast (K) (blue). Bars = 5 µM. (B) Percentage of epimastigotes with 
aberrant morphology after 4 hours treatment with the indicated concentrations of I-17. Boxes are representation 
of median ± max and min values. **p < 0.01 and ***p < 0.001 were calculated using Mann-Whitney U-test 
and Student’s T-test by comparing treated with non-treated cells. Flow cytometry of T. cruzi epimastigotes (C) 
and T. brucei PCF (E) non-treated (NT, black line) or treated for 16 hours with I-17 at 10 µM (red line) stained 
with propidium iodide before flow cytometry analysis. Cell population in G1 and G2 phases are indicated. 
Percentage of population from T. cruzi epimastigotes (D) and T. brucei PCF (F) in G1 and G2 cell cycle phases 
in presence (grey bars) or absence (empty bars) of I-17 are also displayed. The values are means ± standard 
deviation of triplicate experiments and were analyzed with Student´s t-test with *p < 0.05.
www.nature.com/scientificreports/
6ScIEntIFIc RepoRts |  (2018) 8:4857  | DOI:10.1038/s41598-018-23259-9
knockdown lineages showed similar multiplication until 3 days after knockdown induction, but from the third 
to the fourth day of induction, TbK3 knockdowns replicated slightly less (Fig. 4C). Therefore, TbK1 and TbK3 
lineages were tetracycline-induced for 2 or for 4 days previously to the treatment with 3 µM of I-17 for two more 
days. The different effect of I-17 was noticed by expressing the relative number of treated divided by non-treated 
cells (relative cell number), for TbK1 and TbK3 RNAi lineages induced (Ind) or not-induced (NI) (Fig. 4D). 
We observed that the relative cell number was 30% higher 2 or 4 days after induction of the TbK3 knockdown 
compared to the same lineage without RNAi induction. In contrast, TbK1 knockdown induction did not inter-
fere with the inhibition of parasite multiplication caused by I-17. With these data, we demonstrated that, at least 
partially, TbK3 has a role on inducing inhibition of multiplication in T. brucei treated with I-17.
Discussion
In this work, we tested 1,3-di-substituted urea analogs designed and synthesized to activate mammalian heme 
regulated inhibitor and found that among 25 different compounds, I-17, 3p and 6a inhibited T. cruzi epimastig-
otes proliferation (EC50 below 5 µM) with toxicity lower than mammalian cells. Compound I-17 also inhibited the 
intracellular replication of T. cruzi and the proliferative stages of T. brucei, BSF and PCF, with similar EC50 values. 
The selectivity to inhibit intracellular multiplication of T. cruzi was around 17-fold higher than host cell toxicity 
and occurred simultaneously with reversible parasitic cell cycle arrest and inhibition of translation, at least par-
tially, in an eIF2α phosphorylation-dependent manner.
Figure 3. I-17 causes eIF2α phosphorylation and translational initiation impairment. (A) Total extracts of 
exponentially growing T. cruzi epimastigotes (NT), submitted to nutritional stress (TAU), or treated with 10 µM 
of I-17 for 4 hours were analyzed by immunoblotting using antibodies against the phosphorylated threonine 
169 of eIF2α (T169[P]), anti-TceIF2α, and anti-HSP70. The original figures are depicted in as Supplementary 
Figure 2. (B) Ratio between phosphorylated (T169[P]) and the total TceIF2α intensity signal. The values are 
mean ± standard deviation of triplicate experiments and **indicates p < 0.01 calculated using the Student’s 
t-test. (C) Total extracts of exponentially growing T. brucei procyclics (NT) were submitted to 10 µM of I-17 
for 4 or 24 hours and analyzed by immunoblotting using antibodies against the phosphorylated threonine 169 
of eIF2α (T169[P]), anti-TceIF2α used to detect TbeIF2α, and anti-HSP70. (D) Polysome profiles in sucrose 
gradients measured at 254 nm of epimastigotes non-treated (NT) or treated with I-17 at 10 µM. The migrating 
position of the ribosomal subunits (40S and 60S), monosomes (80S) and polysomes (P) is indicated in each 
panel. The P/M ratios were obtained by measuring the graphic area under both fractions.
www.nature.com/scientificreports/
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Figure 4. I-17 inhibition depends on phosphorylatable eIF2α and a specific eIF2α kinase. (A) Relative cell 
numbers after 24 hours were measured in percentages by dividing the total number of T. brucei BSF treated with 
5 µM of I-17 by the cell number of the appointed lineages maintained without I-17 (NT). (+/+) corresponds 
to a parental BSF line, (T169T/−) to BSF containing a single wild type eIF2α gene, and (T169A/−) to BSF 
containing one alelle of eIF2α gene mutated for alanine at T169. The boxes are means ± min and max values of 
quadruplicate experiments. *Indicates p < 0.05 calculated using the Student’s t-test. (B) RT-PCR of total RNA 
extracted from PCF stably transfected using p2T7-177 with segments of TbK1 and TbK3 kinases after four 
days without (NI) or with tetracycline-induction for RNAi expression (Ind). The top panels show a PCR using 
primers for TbK1 and TbK3, and the bottom panels using primers for the enoyl-CoA as an expression control. 
The original gels are shown in the Supplementary Figure 3. (C) Cumulative growth curve of TbK1 (squares) and 
TbK3 (triangles) PCF lineages without (NI) or with tetracycline (Ind) for RNAi induction. The values in (C) are 
means ± standard deviation of triplicate and independent experiments. (D) Relative cell numbers in percentages 
measured as the ratio of total cell numbers of cultures treated with 3 µM I-17 and non-treated cultures (NT), 
www.nature.com/scientificreports/
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As these compounds were shown to present inhibitory activity against melanoma cells26, they could be target-
ing relevant molecules that would allow growth and resistance of transformed cancerous cells as well as parasites. 
Interestingly, cancer cells have to deal with oxidative stresses35, a capacity also critical for T. cruzi virulence36. It 
is noticeable that changes on the 4-aryloxycyclohexyl moiety bearing an N-(3-trifluoromethoxy) phenyl ring, 
designed in 3p, 6a, 3p, 6b di-substituted ureas showed better results against epimastigotes but at the cost of a lower 
selectivity relative to mammalian cells. I-17 was effective at concentration slightly smaller for intracellular amas-
tigotes (1.2 ± 0.5 µM) compared to epimastigotes (3.4 ± 1.3 µM) and the host cell toxicity was variable among 
different cell lines and employed methodology, resulting in a selectivity index ranging from 17 to 9.5. Despite 
this relatively moderate selectivity, the action of I-17 could serve to probe the role of eIF2α in controlling T. cruzi 
infection.
Observations that I-17 promotes formation of enlarged epimastigotes with increasing numbers of cells in 
G1 phase could indicate that I-17 triggered a blockage in the DNA replication (S phase of cell cycle), arresting 
T. cruzi proliferation. Inhibition of replication and a shift in the percentage of G1:G2 cell cycle phases ratio also 
occurred in a similar way for PCF of T. brucei. Nevertheless, this is a well-known phenotype generated by sev-
eral gene knockdowns obtained by RNAi in T. brucei, some of them affecting cell cycle37. Therefore, it is possi-
ble that changes in cell shape and cell cycle might have arisen as consequence of a general trypanosome stress 
response38–40.
We found that I–17 induced phosphorylation of T. cruzi and T. brucei eIF2α at threonine 169 residue (T169), 
which is functionally homologous to the Ser51 of eIF2α in mammalian and yeast cells. On those organisms, it 
is relatively well described how Ser51 eIF2α phosphorylation is responsible for delaying binding of methionine 
initiator tRNA to ribosomes and regulating protein synthesis during stressful conditions41. The T169 phospho-
rylation signal increased in both T. cruzi and T. brucei with time and was associated with decreased levels of 
polysomes, correlating growth inhibition with protein translation decrease. Consistently, T. brucei lineages con-
taining eIF2α with T169 mutated to non-phosphorylatable alanine (T169A/-)42 were relatively more resistant 
to I-17 than control cells containing threonine, a phosphorylatable residue. There is a formal possibility that 
phosphorylation of eIF2α was consequence of stress induced by the compound rather than activation of parasite 
eIF2α kinase, as described for mammalian cells21. For example, a modified urea derivative was shown to interact 
with mammalian CXCR2 receptor preventing signaling43, and fluorinated 1,3-diarylureas were found to activate 
AMP-activated protein kinase, inhibiting cell-cycle progression and proliferation in colorectal and stem cells 
cancers44. This, however, is unlikely to occur in T. cruzi as eight closely related analogs (3b, 3n, 3d, 3j, 3k, 3l, 3t and 
NCPdCPU) which failed to activate mammalian eIF2α kinases also have no activity against parasites23,26.
We noticed that T. brucei BSF T169A/− was only partially resistant to I-17. This partial increase in resistance, 
i.e. cell numbers in presence of I-17 was closer but not equal to the number of cells from untreated cultures, impli-
cates that I-17 may be interfering with other molecular targets mechanisms that affect T. brucei and possibly T. 
cruzi proliferation and/or survival. This partial protection in the non-phosphorylatable lineage (T169A/−) could 
also be explained if parasite cells required some level of eIF2α phosphorylation for stress protection triggered 
by I-17. Alternatively, T169A/− eIF2α lineage could have a different set of expressed proteins, as consequence 
of different translational regulation. Nevertheless, parasite survival could additionally be affected by preventing 
eIF2α phosphorylation, which is known to affect fate decisions in cancerous cells21.
Three eIF2α kinases homologues have been described in Trypanosomatids34,45–47. Here, we further demon-
strated that RNAi knockdown of T. brucei eIF2α kinase 3 (TbK3)33, increased resistance of PCF to I-17. This 
suggests a role for TbK3 kinase as responsible for eIF2α phosphorylation triggered due to I-17 treatment, at least 
in T. brucei. TbK3 has a conserved eIF2α kinase domain34 and it was shown to be essential in regulating spliced 
leader expression by affecting the transcription factor TRF4 after endoplasmic reticulum stress47. Whether TbK3 
can directly phosphorylate eIF2α or targets TRF4 remains to be demonstrated for both trypanosomes, as the 
linkage between these pathways is still obscure. Furthermore, we could speculate that the presence of I-17 could 
activate TbK3, directly or indirectly, inducing eIF2α phosphorylation and causing translation arrest, further pre-
venting spliced leader transcription. This would cause a general growth arrest since spliced leader is added to 
most of the pre-mRNA messengers to allow nuclear export and translation48. This type of response was described 
as an unfolded protein response-like that upon persistence could lead to annexin binding to the parasite and 
DNA fragmentation, independently of caspase activations49, further leading to cell death. Depletion of TbK1, a 
homologous of GCN2 kinase involved in recognizing amino acid starvation on different organisms, including 
Leishmania parasites46, did not change the resistance to I-17. We were not able to obtain knockdowns of TbK2, 
the other eIF2α kinase of T. brucei, so its role in I-17 could not be evaluated.
It is relevant that some 1,3-diarylureas have been tested with some success against flatworm parasites such as 
Schistosoma japonicum50 and Schistosoma mansoni51, although no targets were identified in those cases. Also, a 
family of 1,3-diarylureas with a 4-aminoquinaldinyl as one of the aryl rings was shown to be active against chlo-
roquine sensitive and resistant strains of Plasmodium falciparum52, the causative agent of malaria. 1,3-diarylureas 
have two available cyclic rings that can be readily substituted by various functional groups, allowing the synthesis 
of several improved compounds53. The structure of I-17 could be used to design Trypanosoma kinases activators 
capable of interfering with eIF2α stress responses, potentially useful in combinatory therapies with current drugs, 
such as benznidazole and nifurtimox, known to be potent oxidative stress inducers8,54.
using both TbK1 and TbK3 lineages non-induced with tetracycline (NI, empty bars) or after RNAi induction 
(Ind, grey bars). I-17 treatment was maintained for 48 hours and initiated 2 or 4 days after tetracycline addition. 
The values in (D) are means ± standard deviation of triplicate and independent experiments. *Indicates p < 0.05 
calculated using the Student’s t-test.
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Conclusion
An 1,3-di-substituted urea (I-17) is cytostatic to trypanosomatids partially by promoting phosphorylation of 
eIF2α which causes protein synthesis arrest. Parasites lacking a phosphorylatable eIF2α site or with reduced 
levels of eIF2α-kinase 3 were more resistant to treatment. The compound I-17 also generates an aberrant cell 
morphology and cell cycle arrest. These findings indicate that further exploring the stress response through eIF2α 
regulation could help provide basis to obtain more selective compounds against Trypanosoma parasites compared 
to mammalian cells, especially through quantitative structure activity relationship studies, for example by eluci-
dating the atomic structure of parasite eIF2α kinases.
Material and Methods
Ethics Statement. The procedures used in this work were approved by the “Comite de Ética em Pesquisa da 
Universidade Federal de São Paulo” under protocol 2666291015. All methods were performed in accordance with 
relevant guidelines and regulations approved by the Universidade Federal de São Paulo.
Compounds synthesis and preparation. Discovery, biological and analytical characterization of 
1,3-diarylurea compounds 1-(benzo [d][1,2,3] thiadiazol-6-yl)-3-(3,4-dichlorophenyl) urea (BTdCPU) and 
1-(2-chloro-5- nitrophenyl)-3-(3,4-dichlorophenyl) urea (NCPdCPU) was reported by23. BTdCPU is an activator 
of the activated heme regulated kinase leading to eIF2α phosphorylation, while NCPdCPU is inactive against this 
target. Synthesis and chemical characterization of cHAUs compounds and in vitro and in vivo evaluation have 
been reported elsewhere24,26. Structures of these compounds are shown in Supplementary Figure 1.
Parasites and cell cultures. The bloodstream form (BSF) of T. brucei Lister 427 strain was cultivated in 
HMI-9 medium in the presence of 10% fetal bovine serum (FBS) and Serum Plus (SAFC Biosciences) containing 
59 mg/mL penicillin and 133 mg/mL streptomycin at 37 °C in a CO2 incubator55. We used the T. brucei EATRO 
1125 parental lineage (+/+), or derivatives in which one of the alleles of endogenous gene coding for eIF2α 
was replaced by blasticidin resistance coding sequence and the other allele by either the wild type eIF2α gene 
(T169T/−), or a mutated version in which threonine 169 was replaced by alanine (T169A/−) in a cassette con-
taining the aminoglycoside 3′-phosphotransferase coding sequence that allow resistance to Geneticin G41856. 
These strains were maintained as described above by replacing the FBS by rabbit serum (Sigma-Aldrich) and 
the modified lineages were growth in the presence of 2.5 µg/mL Geneticin-G418 and 5 µg/mL blasticidin (both 
from Thermo Fisher Fisher). The procyclic form (PCF) of T. brucei Lister 427 and its derivative 29–1357 were 
cultivated at 28 °C in SDM-79 medium58 supplemented with 10% FBS and 7.5 µg/mL hemin. For 29–13 PCF, 
50 µg/mL hygromycin B and 15 µg/mL Geneticin-G418 were also added. BSF and PCF were diluted to 2 × 105/mL 
and incubated in medium containing the indicated concentrations of compounds previously diluted in DMSO. 
Epimastigotes of T. cruzi (Y strain) were cultivated at 28 °C in autoclaved liver infusion tryptose (LIT) medium 
supplemented with 1 µg/mL hemin, 10% FBS, 4 mg/mL glucose, 59 mg/mL penicillin and 133 mg/mL strepto-
mycin59. The epimastigotes were diluted to 2 × 106/mL and incubated with the indicated concentrations of com-
pounds. Multiplication of T. brucei and T. cruzi were assessed by counting the number of parasites after 24, 48 and 
72 hours respectively, using hemocytometer in three independent experiments.
Tissue culture derived T. cruzi trypomastigotes (TCT) were obtained from supernatants of infected LLC-MK2 
(Rhesus monkey kidney epithelial cells, ATCC CCL-7) cultivated in low glucose Dulbecco’s Modified Eagle 
Medium (DMEM, Thermo Fisher Scientific) supplemented with 3.7 g/L sodium bicarbonate, 10% FBS, 59 mg/mL 
penicillin and 133 mg/mL streptomycin at 37 °C in a CO2 incubator. The parasites were collected by centrifugation 
at 1500 g for 5 min, incubated for at least 60 min at 37 °C and the TCT enriched supernatants were collected to be 
used for new infections. LLC-MK2, L6 rat myoblasts (ATCC CRL-1458) and U-2 OS (Banco de Células do Rio 
de Janeiro, Brazil) maintained in the same medium were used for evaluating the progression of T. cruzi infection. 
The cells (1 × 105) were seeded onto 13 mm glass coverslips in 24 well plates and incubated at 37 °C. The next 
day, 5 × 105 TCT in 500 µL were added to each well and incubations proceeded for 2 hours. Wells were washed 
twice with PBS and incubation continued in the presence of culture medium with the indicated amounts of each 
compound. After 72 hours, the cells were fixed in Bouin solution (acetic acid 5%, formaldehyde 9% and picric 
acid 0.9%) for 5 min and washed four times with PBS before staining for 1 hour with Giemsa solution (previously 
diluted 1:10 in tap water and filtered). Glass coverslips were dehydrated in acetone, acetone with xylol, and only 
xylol before mounted in glass slides covered with Entellan mounting medium (Sigma-Aldrich). Coverslips were 
visualized under an optical microscope and the number of intracellular amastigotes assessed in one hundred 
infected cells.
Parasite viability assays and EC50 determination. T. cruzi epimastigotes at 1 × 107/mL in 50 µL were 
incubated in 96-wells plates with the same volume of compounds pre-diluted in 50 µL of LIT medium for 48 hours 
at 28 °C. LLC-MK2 cells (3 × 103) in 100 µL of medium were added to 96 well plates. After 5 hours, the medium 
was replaced by fresh medium containing serial dilutions of test compounds and incubations proceeded for 
72 hours at 37 °C. In both cases, 10 µL of AlamarBlue (Thermo Fisher Scientific) was added and the plates were 
further incubated for 18 hours at 28 °C for epimastigotes and 4 hours at 37 °C for mammalian cells. Absorbance 
at 570 nm and 600 nm were measured by using a SpectraMax M3 (Molecular Devices). The differences between 
absorbance at 570 nm and 600 nm for each well was normalized against a blank value for medium without par-
asites and lysed cells. Alternatively, L6 rat myoblast cell death and lysis were determined using the cytotoxic-
ity Detection Kit Plus LDH Version 6 (Roche) after 72 hours incubation with the indicated compounds using 
the manufacturer protocol. Data was analyzed using GraphPad Prism 6.01 software with logarithmic nonlinear 
regression to generate a response curve fitting and determine the effective concentration that affects 50% of cells 
(EC50) or 90% of cells (EC90). Each compound was tested in triplicates in at least two independent experiments, 
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with exceptions appointed on Table 1. Selective index was estimated by the ratio between LLC-MK2 EC50 and 
epimastigotes EC50 on Table 1.
High content analysis of T. cruzi infection. To evaluate resistance to I-17 during intracellular amastigote 
replication, we used a system of high content imaging analysis that allowed processing of thousands of cells to 
robustly evaluate inhibitory effects on intracellular T. cruzi multiplication simultaneously to evaluation of host 
cell toxicity. Stock solution of I-17 was diluted to 5.7 mM in DMSO. Before use, the compound was transferred 
onto 384-well polypropylene stock plates (Greiner Bio-One) and further diluted into 10-point dose response 
curve (2-fold serial dilution) in neat DMSO. These stock plates were kept frozen at −20 °C and protected from 
light.
U-2 OS cells were plated at 800 cells per well in 40 μL of medium and incubated for 24 hours at 37 °C. The 
cells were then infected with 10 μL of trypomastigotes suspension at 1.5 × 106/mL, harvested from the superna-
tant of LLC-MK2 cultures. The next day, serially diluted I-17 solutions were transferred into intermediate plate 
containing culture medium in order to decrease DMSO and I-17 highest concentration to 6% (v/v) and 342 µM, 
respectively. Finally, ten microliters of compound solution were transferred onto assay plates, yielding a final 
concentration of 1% DMSO (v/v) in a final volume of 60 μL, starting from 57 µM of I-17. DMSO-treated wells 
containing non-infected and infected cells were used as positive and negative controls, respectively. After 4 days 
at 37 °C, the cells were fixed with 4% paraformaldehyde diluted in PBS (PFA), stained with Draq5 (Biostatus) 
for 30 minutes at room temperature in the dark, and six images per well, totalizing more than a thousand cells, 
were acquired using the high content imaging system INCell 2200 (General Electric) at 20× agnification. Images 
were analyzed by using Investigator, version 1.6 (General Electric) for identification, segmentation and quan-
tification of host cell nucleus, cytoplasm and intracellular parasites. The analysis provided output data for all 
images as the total number of cells, total number of infected cells and the total number of intracellular parasites. 
The infection ratio was obtained by considering the number of infected cells relative to the total number of cells 
and was normalized to the infections obtained in the presence of 1% DMSO (negative control) and non-infected 
cells to calculate the normalized antiparasitic activity, according to the following formula: Normalized Activity 
(NA) = [1− (Average IRN − Average IRT)/(Average IRN – Average IRP)] × 100. Where IRN is the infection ratio 
of negative control wells, IRP is the infection ratio of positive control wells and IRT is the infection ratio of test 
compound wells. The final results of compound activity define the percentage of T. cruzi free cells normalized to 
control values.
Dose-response curves were processed with Graphpad Prism software, version 6, for generation of sigmoi-
dal dose-response (variable slope) nonlinear curve fitting and determination of EC50 values by interpolation. 
Percentage of host cell survival was calculated as a relation between the number of cells on treated wells relative to 
the number of cells in non-treated wells as an indicative of cytotoxicity and replication inhibition.
Immunofluorescence. Exponentially growing T. cruzi epimastigotes were diluted in medium to 8 × 106/
mL and incubated with the indicated compounds. At the end of treatments, cells were collected by centrifu-
gation at 2000 g for 2 min, washed and resuspended in PBS before addition to glass slides (Tekdon Inc.) previ-
ously coated with 0.01% poly-L-lysine (Sigma-Aldrich) for 20 min. After 5 min, the unattached parasites were 
removed, and the slides were incubated with PFA, washed with PBS and permeabilized with 0.1% Triton X-100 
in PBS for 5 min. The slides were then incubated 20 min with 1% BSA in PBS, followed by 1 hour incubation 
with a mouse antibody against β-tubulin C-terminal peptide45 diluted 1:1000 in blocking solution. The slides 
were washed with PBS, incubated 1 hour in the dark with anti-rabbit IgG antibody coupled to Alexa Fluor 488 
(Thermo Fisher Scientific) at 1:1000 in PBS and 10 µg/mL 4′,6-diamidino-2-phenylindole (DAPI). Slides were 
washed twice with PBS and mounted with Prolong Gold Antifade Reagent (Thermo Fisher Scientific). Images 
were acquired using a Hamamatsu Orca R2 CCD camera coupled to an Olympus BX-61 microscope equipped 
with an x100 plan Apo-oil objective (NA 1.4). AutoQuant X2.2 software (Media Cybernetics) was used to per-
form blind deconvolution.
Cell cycle analysis. After the indicated treatments, parasites were collected by centrifugation at 2000 g for 
2 min, washed in PBS, fixed with 50% cold methanol for 10 min and washed in PBS again. To eliminate RNA 
background staining, the cells were incubated with RNAse (10 µg/mL) for 30 min at 37 °C, washed once more 
with PBS and diluted in 1 mL of PBS containing 10 µg of propidium iodide for 5 min. Parasites were quickly 
washed twice with PBS and analyzed in a BD Accuri C6 (BD Sciences) flow cytometry using FL-2 channel for 
fluorescence detection.
Immunoblotting. Parasites treated as indicated were collected by centrifugation at 2000 g for 5 min and 
washed once in TBS (50 mM Tris-HCl pH 7.5, 150 mM NaCl) before addition of Laemmli buffer and heat dena-
turation at 95 °C for 5 min. Electrophoresis in polyacrylamide gels containing SDS and transfer to nitrocellulose 
membranes were performed by standard procedures. The membranes were stained with 0.5% Ponceau S in 3% 
acetic acid and cut separating the portion containing proteins with mass above and below 60 and 40 kDa. All 
membranes pieces were blocked with TBS containing 0.1% Tween 20 (TBS-T) and 5% BSA overnight. Membrane 
pieces from 40 kDa to 60 kDa were incubated for 3 hours with affinity purified antibodies reacting with the phos-
phorylated T169 (T169[P]) of T. cruzi eIF2α31 diluted 1:125 in blocking buffer. The primary antibody was washed 
3 times in TBS-T for 10 min and incubated for 1 hour with anti-rabbit IgG peroxidase-conjugated antibody 
(Thermo Fisher Scientific) diluted 1:20000 in TBS. Membranes were washed three times in TBS-T for 10 min 
and bound antibodies detected by ECL (EMD Millipore) by using an Odyssey Fc System (LI-COR Biosciences). 
The same membrane pieces were re-probed with an antiserum (anti-TceIF2α) obtained by immunization of mice 
with a recombinant T. cruzi eIF2α expressed in Escherichia coli31. The serum was diluted 1:2000 in PBS containing 
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5% non-fat dry milk and after 1 hour incubation the membranes were washed three times with TBS-T followed 
by 1 hour incubation with anti-mouse IgG IRDye 800 (LI-COR Biosciences) 1:10000 in PBS. Membranes were 
washed three times with TBS-T and bound antibodies detected as described above. The nitrocellulose pieces from 
60 kDa to the membrane upper edge were incubated with rabbit serum anti-HSP7060 diluted 1:10000 in blocking 
buffer for 1 h, washed three times with TBS-T and incubated with secondary anti-rabbit IgG IRDye 680 (LI-COR 
Biosciences) 1:10000 on TBS for 1 hour before another three washes in TBS-T and detection with Odyssey Fc 
System.
Polysome profiling. At least 1 × 109 of exponentially growing parasites were treated with the indicated con-
centrations of inhibitors. After 24 h, cycloheximide was added to 100 µg/mL and the cells maintained at 28 °C for 
10 min before further incubation on ice for 10 min, centrifuged 5 min at 2000 g at 4 °C, washed in ice-cold PBS 
containing the same concentration of cycloheximide and diluted in 300 µL of ice-cold Buffer A (10 mM Tris-HCl, 
pH. 7.4, 300 mM KCl, 10 mM MgCl2, 1 mM dithiothreitol and 100 µg/mL cycloheximide). A small drop of Triton 
X-100 was added on the lateral side of tube to reach 1% (v/v) and the tubes were repeatedly mixed by inversion 
for about 5 min. The lysates were centrifuged for 3 min at 5000 g at 4 °C and the supernatant collected and added 
to a new tube. Stocks of heparin at 100 mg/mL and NaCl at 5 M were added to 1 mg/mL and 150 mM respectively. 
The corresponding volume of the samples containing the equivalent of ten absorbance units at 260 nm were then 
loaded on the top of a 7% to 47% sucrose gradient in Buffer A prepared using a Gradient Master (Biocomp). The 
tubes were centrifuged at 200,000 g for 2.5 hours in a Beckman SW41 rotor at 4 °C. The gradient was collected 
from the top by injecting in the bottom a continuous flow of 60% sucrose at 1 mL/min using an Econo Gradient 
Pump (Bio-Rad) and the fractions monitored by reading the absorbance at 254 nm.
T. brucei eIF2α-kinases knockdown. A small fragment of the coding sequence between residues 2595 and 
3066 of the T. brucei eIF2α-kinase 1 (TbK1, tritrypdb.org: Tb927.11.7210) and residues 1479 to 1989 eIF2α-kinase 
3 (TbK3, tritrypdb.org: Tb927.6.2980) were PCR amplified from genomic DNA of T. brucei EATRO 1125 
strain using the following oligonucleotides: TbK1XbaFow (5′-GCTCTAGATGTGAGTCCATTGAACCGGG) 
and TbK1XhoRev (5′-GCTCGAGTAAACGTCCTGAGGCCGAAC) and TbK3XbaFow (5′-GCTCGAGA 
ACTCCAGCACAATCCTCCG) and TbK3XhoRev (5′-GCTCGAGAACTCCAGCGCAATCCTCCG). The fragments 
were digested with XhoI and XbaI and cloned into XhoI and XbaI restriction sites of the p2T7–177 plasmid61 to 
generate inducible knockdowns in PCF 29–13 strain57. The obtained plasmids were linearized with NotI, purified 
with QIAquick Gel Extraction Kit (Qiagen), diluted in 200 µL of Zimmerman’s Post Fusion Medium (ZPMF) 
containing 108 PCF of 29–13 strain, and pulsed in 0.2 mm cuvettes with X-014 program on Amaxa Nucleofactor 
(Lonza). The cells were then diluted in SDM-79 medium and selection was done by adding 2.5 µg/mL phleomy-
cin. After selection, expression of double-strand RNA for TbK1 or TbK3 knockdown induction was obtained by 
adding 1 µg/mL tetracycline daily.
RT-PCR. Total RNA was extracted from the parasites using Trizol (Thermo Fisher Scientific) and treated 
with 2 U of DNAse I per µL for 30 min at 37 °C. The enzyme was inactivated by 10 min incubation at 75 °C 
and 10 µg of the denatured RNA was incubated with 1 µM of oligo-dT, cooled on ice, and then incu-
bated for 50 min at 50 °C with Superscript III reverse transcriptase (Thermo Fisher Scientific) in the pres-
ence of the recommend buffer, 5 mM dNTP, 2 mM DTT and 40 U RNase out (Thermo Fisher Scientific) 
in a final volume of 50 µL. The enzyme was inactivated at 70 °C for 15 min and the produced cDNA treated 
with RNAse H (2U) at 37 °C for 20 min. A PCR reaction was performed using 25 cycles at 62 °C for anneal-
ing using the following pair of oligonucleotides: TbK1Fq (5′-TCCGGAGAGTGTCAGCGGGT)/TbK1Rq 
(5′-TGTGGCTGAGAGCGGCCAAAC), and TbK3Fq (5′-GGGGTGAGTGGGAAAGGACGTG)/TbK3Rq 
5′-GCCGAGGCACCGAAAGTCCC) to amplify the residues 788 to 985 of TbK1Fq and residues 424 to 
619 of TbK3, respectively. Amplification of enoyl-CoA, a non-related protein of T. brucei62, was performed 
as a control using Enoyl_CR3_F (5′CGCATATGTTACGCTCCTGTGCACTTTTA) and Enoyl-CR3_R 
(5′CGCTCGAGCTACGAATTGGTGAAGAACGGTTT).
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